Daan Guido Maria Van Well, an officer of SOPHiA GENETICS SA, filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 1,411 shares of common stock on NASDAQ under a Rule 10b5-1 plan.

Key Highlights

  • Proposed sale: Van Well intends to sell 1,411 shares of SOPHiA GENETICS SA common stock, with an aggregate market value of $10,074.54, according to the filing.
  • Shares outstanding: The filing reports 85,658,321 shares of common stock outstanding at the time of notice.
  • Acquisition origin: The 1,411 shares were acquired on April 28, 2022, through a Restricted Stock Unit grant from the issuer.
  • 10b5-1 plan date: The filing states the trading plan was adopted on June 11, 2026.
  • Broker: Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004, is named as the broker for the proposed sale.
  • Prior sales in past three months: The filing discloses two prior 10b5-1 sales by Van Well: 6,168 shares sold on October 5, 2026, for gross proceeds of $50,100.20, and 6,168 shares sold on September 11, 2026, for gross proceeds of $47,088.98.

Van Well's Proposed Sale and Recent Transaction History at SOPHiA GENETICS

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Daan Guido Maria Van Well, identified as an officer of SOPHiA GENETICS SA (NASDAQ:SOPH), proposes to sell 1,411 shares of the company's common stock. The filing lists an approximate sale date of November 9, 2026, with an aggregate market value of $10,074.54. The shares are to be sold on the NASDAQ exchange through Morgan Stanley Smith Barney LLC Executive Financial Services.

The filing discloses that the 1,411 shares were originally acquired on April 28, 2022, via a Restricted Stock Unit grant from the issuer, with a payment date also listed as April 28, 2022. The notice indicates the sale is being conducted pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2026. As of the filing date, the company's total shares of common stock outstanding are reported as 85,658,321.

In the section covering securities sold during the past three months, the filing reports two prior transactions under a 10b5-1 plan for Van Well: a sale of 6,168 shares on October 5, 2026, generating gross proceeds of $50,100.20, and a sale of 6,168 shares on September 11, 2026, generating gross proceeds of $47,088.98. Both prior sales are listed at the same issuer address in Rolle, Switzerland.

What Was Disclosed

SOPHiA GENETICS SA officer Daan Guido Maria Van Well filed a Form 144 on November 9, 2026, disclosing a proposed sale of 1,411 shares of common stock valued at $10,074.54, acquired through Restricted Stock Units in 2022, under a 10b5-1 plan adopted June 11, 2026.